Feature | June 20, 2014

Injection timing and increased dose of a common imaging agent boosts detection of advanced malignancy of the breast and lymph nodes


June 20, 2014 — Patients with advanced breast cancer that may have spread to their lymph nodes could benefit from a more robust dose of a molecular imaging agent called Tc-99m filtered sulfur colloid when undergoing lymphoscintigraphy, a functional imaging technique that scouts new cancer as it begins to metastasize. Best results also indicate that imaging could be improved by injecting the agent the day prior to surgical resection, according to research unveiled at the 2014 annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).

“The innovative aspect of this study was our recent introduction of day-before-surgery injections for breast cancer patients,” said Donald Neumann, M.D., research scientist and practicing physician from the department of nuclear medicine at Cleveland Clinic in Ohio. “Prior to this, we routinely injected patients on the day of surgery. There were several motivating factors for us to do this. Typically, surgeries begin very early in the morning, and it is very difficult to arrange all the necessary equipment, personnel and radiotracers early enough in the morning for patients to be injected, scanned, have their images interpreted and travel (or be transported) to surgical check-in.”

The researchers also enhanced the activity of the agent as imaged by lymphoscintigraphy, by increasing the standard patient dose to 3.0 millicuries of Tc-99m filtered sulfur colloid, up from 0.4 millicuries.

The change in injection timing from the morning of surgery to the day prior to surgery was based on study data. Of a group of 51 patients who were imaged the day prior, 39 had cancer that had spread to their lymph nodes and 12 patients’ scans showed multiple lymph node malignancy. A separate group of 49 patients were injected with the agent the morning of their surgery. Of these, 24 patients had cancer that had metastasized to their lymph nodes. Imaging the morning prior ended up being more sensitive for the detection of advanced breast cancer than the day of, 76 percent sensitive versus 49 percent, respectively.

For more information: www.snmmi.org


Related Content

News | Breast Imaging

Nov. 17, 2025 — RadNet, Inc. and its wholly owned subsidiary, DeepHealth have announced results from the largest real ...

Time November 17, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Artificial Intelligence

Nov. 6, 2025 — Lunit, a provider of AI for cancer diagnostics and precision oncology, recently announced that Volpara ...

Time November 07, 2025
arrow
News | RSNA 2025

Nov. 3, 2025 — QT Imaging Holdings has announced that its chief medical officer, Elaine luanow, MD, will host a seminar ...

Time November 04, 2025
arrow
News | Breast Imaging

Oct. 28, 2025 — QT Imaging Holdings, Inc., a medical device company focused on radiation-free imaging technology, has ...

Time October 28, 2025
arrow
Feature | Breast Imaging

Despite decades of progress in breast imaging, one challenge continues to test even the most skilled radiologists ...

Time October 24, 2025
arrow
News | Breast Imaging

Oct. 15, 2025 — Leading into Breast Cancer Awareness Month, Fujifilm Healthcare Americas Corp. and Beekley Medical ...

Time October 15, 2025
arrow
News | Breast Imaging

Oct. 3, 2025 — Gnosis for Her, a mobile breast health initiative redefining comfort and access in women's breast imaging ...

Time October 06, 2025
arrow
News | Mammography | Mayo Clinic

Early detection is key to breast cancer survival. But nearly half of all women in the U.S. have dense breast tissue ...

Time October 03, 2025
arrow
Subscribe Now